Announcing its financial results for 2023, diversified German drugmaker (BAYN: DE) said it would delay a plan to break up the group for at least a couple of years.
The firm reported sales of 11.9 billion euros ($12.9 billion) in the last quarter, a rise of 5.5%, and 47.6 billion euros for the full year.
Net income was 1.3 billion euros for the quarter, with a loss of 2.9 billion euros for the year as a whole, leading respectively to earnings per share (EPS) of 1.36 euros and minus three euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze